ストックスクリーナーアプリを入手
32.17
2.69%
-0.89
アフターアワーズ：
32.17
前日終値:
$33.06
開ける：
$32.52
24時間の取引高:
1.47M
Relative Volume:
1.03
時価総額：
$4.18B
収益：
-
当期純損益:
$-507.65M
株価収益率:
-6.9935
EPS:
-4.6
ネットキャッシュフロー:
$-616.24M
1週間 パフォーマンス:
-2.57%
1か月 パフォーマンス:
+7.23%
6か月 パフォーマンス:
-56.08%
1年 パフォーマンス:
-71.81%
1日の値動き範囲:
$31.77
$32.88
1週間の範囲:
$31.47
$33.67
52週間の値動き範囲:
$27.66
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
名前
Vaxcyte Inc
セクター
電話
650-837-0111
住所
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
PCVX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
32.17 | 4.15B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-20 | 開始されました | Goldman | Buy |
| 2023-12-07 | 開始されました | Mizuho | Buy |
| 2023-04-18 | 開始されました | TD Cowen | Outperform |
| 2023-01-03 | 繰り返されました | Needham | Buy |
| 2022-12-15 | 開始されました | Guggenheim | Buy |
| 2022-11-17 | 開始されました | BTIG Research | Buy |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-06-24 | 再開されました | Jefferies | Buy |
| 2020-07-07 | 開始されました | BofA Securities | Buy |
| 2020-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 開始されました | Needham | Buy |
すべてを表示
Vaxcyte Inc (PCVX) 最新ニュース
Alliancebernstein L.P. Sells 75,151 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Polar Asset Management Partners Inc. Invests $378,000 in Vaxcyte, Inc. $PCVX - MarketBeat
FMR LLC's Strategic Acquisition of Vaxcyte Inc Shares - GuruFocus
Vaxcyte (PCVX) Initiates Coverage with Neutral Rating by Goldman Sachs | PCVX Stock News - GuruFocus
Goldman Sachs initiates Vaxcyte stock coverage with Neutral rating By Investing.com - Investing.com Canada
TSCM U.S. Small Cap Growth Strategy Exited Vaxcyte (PCVX) as Its Infant Trial was Less Than Compelling - uk.finance.yahoo.com
Vaxcyte, Inc. $PCVX Shares Sold by Woodline Partners LP - MarketBeat
Fred Alger Management LLC Cuts Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Jones Financial Companies Lllp Has $6.27 Million Stock Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Amundi Reduces Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte Stock Price, Quotes and Forecasts | NASDAQ:PCVX - Benzinga
Alyeska Investment Group L.P. Sells 32,945 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc. $PCVX Shares Sold by Parkman Healthcare Partners LLC - MarketBeat
Can Vaxcyte Inc. continue delivering strong returnsJuly 2025 Price Swings & Accurate Entry/Exit Alerts - Lancaster City Council
Cormorant Asset Management LP Lowers Position in Vaxcyte, Inc. $PCVX - MarketBeat
What is Vaxcyte Inc. s 5 year growth outlook2025 Trading Recap & AI Driven Stock Reports - beatles.ru
Is Vaxcyte Inc.’s growth already priced inWeekly Stock Report & Fast Exit and Entry Trade Guides - beatles.ru
Allostery Investments LP Takes $1.21 Million Position in Vaxcyte, Inc. $PCVX - MarketBeat
First Light Asset Management LLC Makes New Investment in Vaxcyte, Inc. $PCVX - MarketBeat
What indicators show strength in Vaxcyte Inc.Weekly Investment Summary & Growth Oriented Trade Recommendations - Newser
ADAR1 Capital Management LLC Makes New $483,000 Investment in Vaxcyte, Inc. $PCVX - MarketBeat
What are Vaxcyte Inc.’s growth leversRate Hike & Daily Profit Maximizing Tips - خودرو بانک
What are Vaxcyte Inc.’s recent SEC filings showingNew Guidance & Daily Chart Pattern Signal Reports - خودرو بانک
Vaxcyte, Inc. shares rise 3.73% intraday after presenting at Cantor Global Healthcare Conference. - AInvest
Vaxcyte Inc. stock outlook for YEARJuly 2025 Catalysts & Weekly High Momentum Picks - Newser
Short interest data insights for Vaxcyte Inc.2025 Momentum Check & Fast Moving Stock Watchlists - Newser
Vaxcyte Inc. stock trend forecastGold Moves & Free Safe Entry Trade Signal Reports - Newser
Is Vaxcyte Inc. forming a bottoming base2025 Key Highlights & Risk Controlled Stock Alerts - Newser
Will Vaxcyte Inc. stock recover after earningsQuarterly Portfolio Report & Long-Term Safe Investment Ideas - خودرو بانک
Advanced analytics toolkit walkthrough for Vaxcyte Inc.Earnings Miss & High Conviction Investment Ideas - Newser
Is Vaxcyte Inc. stock technically oversoldMarket Trend Review & Proven Capital Preservation Tips - خودرو بانک
Raymond James Financial Inc. Acquires 28,430 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
How to forecast Vaxcyte Inc. trends using time seriesJuly 2025 Summary & Daily Price Action Insights - Newser
Multi factor analysis applied to Vaxcyte Inc.2025 Earnings Impact & Weekly Market Pulse Updates - Newser
How to interpret RSI for Vaxcyte Inc. stockJuly 2025 Catalysts & Consistent Income Trade Recommendations - Newser
Live market analysis of Vaxcyte Inc.Weekly Profit Report & Safe Entry Point Identification - Newser
Is Vaxcyte Inc. forming a reversal patternJuly 2025 Intraday Action & AI Forecasted Entry and Exit Points - Newser
Vaxcyte advances VAX-31 pneumococcal vaccine to final stage of infant study - Investing.com Canada
Visualizing Vaxcyte Inc. stock with heatmapsEarnings Miss & Advanced Swing Trade Entry Alerts - Newser
Analyzing Vaxcyte Inc. with risk reward ratio charts2025 Support & Resistance & Safe Swing Trade Setups - Newser
Vaxcyte shares rise 1.90% after-hours as VAX-31 Phase 2 study advances to final stage. - AInvest
Vaxcyte Says VAX-31 Pneumococcal Disease Study Advances to Final Stage - MarketScreener
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose - The Manila Times
Vaxcyte Advances VAX-31 Infant Phase 2 Study with New Optimized Dose Aimed at Enhancing Immune Response Against Invasive Pneumococcal Disease - Quiver Quantitative
92% Disease Coverage: Vaxcyte's VAX-31 Could Become Broadest Pneumococcal Vaccine for Infants - Stock Titan
What recovery options are there for Vaxcyte Inc.2025 Top Gainers & High Conviction Investment Ideas - Newser
How to build a custom watchlist for Vaxcyte Inc.July 2025 Update & Community Supported Trade Ideas - Newser
Evaluating Vaxcyte Inc. with trendline analysisWeekly Profit Summary & Long Hold Capital Preservation Tips - Newser
How institutional ownership impacts Vaxcyte Inc. stockMarket Sentiment Report & Verified Swing Trading Watchlist - Newser
What is the target price for Vaxcyte Inc. stock2025 Trading Volume Trends & Trade Opportunity Analysis Reports - khodrobank.com
Vaxcyte Inc (PCVX) 財務データ
収益
当期純利益
現金流量
EPS
Vaxcyte Inc (PCVX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 07 '25 |
Option Exercise |
20.93 |
4,777 |
99,983 |
131,950 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
8.96 |
20,533 |
183,888 |
518,775 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Option Exercise |
21.41 |
5,000 |
107,050 |
46,620 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Sale |
70.74 |
5,000 |
353,699 |
41,620 |
0.93%
0.10%
大文字化:
|
ボリューム (24 時間):